Background Cardiac resynchronisation therapy (CRT) improves symptoms and prognosis in patients with heart failure and cardiac dyssynchrony. Guidelines from the National Institute of Clinical Excellence in the United Kingdom recommend CRT for patients with moderate or severe symptoms that either recent or persistent. We investigated whether the severity of symptoms was an important determinant of the prognostic benefits of CRT.
Methods Data from the CARE-HF trial, which randomly assigned 813 patients with left ventricular ejection fraction ,,T35% and markers of cardiac dyssynchrony who were in the investigators opinion in New York Heart Association (NYHA) class III/IV, to pharmacological treatment alone or with the addition of CRT, were analysed to determine whether the severity of symptoms reported by patients influenced prognosis and the response to CRT. Symptoms of heart failure were assessed using Likert Scales from the EuroHeart Failure Questionnaire, which also records patients i: self-assessed NYHA class.
Results Patients assessed themselves to be in NYHA class I or II in 175 cases (21.5%). These patients also reported less severe symptoms and better quality of life than patients who assessed themselves to be in NYHA class III or IV. No statistical interaction was observed between the severity of symptoms assessed in a number of different ways and the benefits of CRT on morbidity and mortality.
Conclusions The severity of symptoms was not an important determinant of the prognostic effects of CRT in patients with moderate or severe LVSD and markers of dyssynchrony in the CARE-HF study. This finding requires confirmation in an adequately powered prospective randomized controlled trial in patients with milder symptoms.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.